Brivaracetam Desitin: Uses, Dosage & Side Effects
A selective SV2A ligand antiepileptic medication used as adjunctive therapy for partial-onset (focal) seizures in adults and adolescents from 16 years of age
Brivaracetam Desitin is a prescription antiepileptic medication containing brivaracetam as its active substance. It is used as adjunctive therapy (add-on treatment) for partial-onset seizures (focal seizures), with or without secondary generalization, in adults and adolescents aged 16 years and older who are already taking other antiepileptic medications. Brivaracetam works by binding with high selectivity to synaptic vesicle protein 2A (SV2A) in the brain, modulating neurotransmitter release and reducing abnormal neuronal excitability. Available as 10 mg film-coated tablets, it offers flexible dosing from 50 mg to 200 mg per day, taken in two divided doses. Clinical trials have demonstrated that brivaracetam significantly reduces seizure frequency compared to placebo, with a generally well-tolerated safety profile.
Quick Facts: Brivaracetam Desitin
Key Takeaways
- Brivaracetam Desitin is a next-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with approximately 15–30 times higher affinity than levetiracetam, offering potent seizure control as adjunctive therapy for focal seizures.
- The recommended dose range is 50–200 mg per day, divided into two equal doses (morning and evening), with or without food. The starting dose can be initiated without a titration period, allowing for rapid onset of therapeutic effect.
- Clinical trials (N01358, N01252, N01253) demonstrated significant reductions in focal seizure frequency, with the 50 mg, 100 mg, and 200 mg daily doses all showing superiority over placebo.
- The most common side effects are dizziness, somnolence (drowsiness), and fatigue, which are generally mild to moderate and tend to diminish over time as the body adjusts to the medication.
- Brivaracetam has a favorable pharmacokinetic profile with nearly 100% oral bioavailability, linear pharmacokinetics, minimal protein binding, and limited potential for clinically significant drug interactions compared to many older antiepileptic drugs.
What Is Brivaracetam Desitin and What Is It Used For?
Brivaracetam Desitin contains the active substance brivaracetam, a chemical analogue of levetiracetam belonging to the pyrrolidone class of antiepileptic drugs. It was specifically designed to achieve higher selectivity and affinity for its molecular target, synaptic vesicle protein 2A (SV2A), than its predecessor levetiracetam. SV2A is an integral membrane glycoprotein present in the membranes of synaptic vesicles across virtually all neurons in the brain. This protein plays a crucial role in regulating the process of neurotransmitter release at synapses, the junctions where nerve cells communicate with one another.
Under normal conditions, when a nerve impulse reaches the end of a neuron (the presynaptic terminal), synaptic vesicles containing neurotransmitters fuse with the cell membrane and release their contents into the synaptic cleft. In epilepsy, there is an imbalance in this signaling process, leading to excessive and synchronized neuronal firing that manifests as seizures. By binding to SV2A with high selectivity and approximately 15 to 30 times greater affinity than levetiracetam, brivaracetam modulates the process of synaptic vesicle exocytosis and neurotransmitter release. This mechanism reduces neuronal hyperexcitability and inhibits the spread of seizure activity through neuronal networks, without broadly suppressing normal brain function.
The precise way in which SV2A modulation leads to antiepileptic effects is still an area of active research. However, preclinical studies have demonstrated that brivaracetam displays potent anticonvulsant activity in multiple animal models of epilepsy, including models of both generalized and focal seizures. Electrophysiological studies have shown that brivaracetam decreases the rate of high-frequency firing in neurons without affecting normal low-frequency firing, which may explain why it can reduce seizure activity while preserving normal neurological function. Additionally, brivaracetam has been shown to reverse the effects of rapid kindling in animal models, suggesting it may have antiepileptogenic properties, although this has not yet been demonstrated in humans.
Brivaracetam Desitin is indicated as adjunctive therapy for the treatment of partial-onset seizures (also known as focal seizures) with or without secondary generalization in adults and adolescents from 16 years of age with epilepsy. Focal seizures originate in a specific area of the brain and can produce a wide range of symptoms depending on the brain region involved. Simple focal seizures occur without loss of consciousness and may cause involuntary movements, sensory disturbances, or emotional changes. Complex focal seizures involve impaired awareness or consciousness and may include automatisms (repetitive, involuntary movements such as lip-smacking or hand-wringing). Some focal seizures can spread to involve the entire brain, becoming secondarily generalized tonic-clonic seizures with loss of consciousness, stiffening, and rhythmic jerking of the limbs.
The clinical efficacy of brivaracetam in focal seizures has been established through three pivotal phase III randomized, double-blind, placebo-controlled trials:
- Study N01358: This trial enrolled 768 adults with uncontrolled focal seizures despite treatment with 1–2 other antiepileptic drugs. Patients were randomized to placebo, brivaracetam 50 mg/day, or brivaracetam 100 mg/day for a 12-week treatment period. Both brivaracetam doses demonstrated statistically significant reductions in 28-day adjusted focal seizure frequency compared to placebo. The 50 mg/day group achieved a median percent reduction of 22.8% over placebo, while the 100 mg/day group achieved 22.0% over placebo.
- Study N01252: This trial enrolled 400 patients randomized to placebo or brivaracetam 50 mg/day. The brivaracetam group showed a significant 12.8% reduction in 28-day adjusted focal seizure frequency over placebo. The 50% responder rate (proportion of patients achieving at least a 50% reduction in seizure frequency) was significantly higher in the brivaracetam group.
- Study N01253: This trial enrolled 760 patients randomized to placebo, brivaracetam 100 mg/day, or brivaracetam 200 mg/day. Both doses showed statistically significant reductions in seizure frequency compared to placebo, with the 200 mg/day dose producing the most robust effect. Importantly, this trial also demonstrated that brivaracetam was effective regardless of whether patients were concurrently taking levetiracetam, although the magnitude of benefit was somewhat reduced in patients already receiving levetiracetam.
Long-term open-label extension studies have demonstrated that the seizure-reducing effects of brivaracetam are sustained over periods of up to 8 years of continuous treatment, with no evidence of tolerance developing. Approximately 5–10% of patients in long-term studies achieved complete seizure freedom for periods of 6 months or longer. Brivaracetam was first approved by the European Medicines Agency (EMA) in January 2016 under the trade name Briviact and subsequently by the U.S. Food and Drug Administration (FDA) in February 2016. Brivaracetam Desitin is a generic formulation manufactured by Desitin Arzneimittel GmbH, containing the same active ingredient and demonstrating bioequivalence to the originator product.
While both brivaracetam and levetiracetam target SV2A, brivaracetam was specifically engineered to have 15–30 times greater binding affinity for SV2A. This higher selectivity translates into potent antiseizure activity at lower doses, rapid onset of action (no slow titration required), and a potentially improved behavioral side effect profile. Several clinical studies have suggested that brivaracetam may be better tolerated in terms of psychiatric and behavioral side effects compared to levetiracetam, making it a viable alternative for patients who experienced irritability, aggression, or mood disturbances on levetiracetam.
What Should You Know Before Taking Brivaracetam Desitin?
Contraindications
Brivaracetam Desitin is contraindicated in patients with known hypersensitivity to brivaracetam, to other pyrrolidone derivatives (such as levetiracetam or piracetam), or to any of the excipients contained in the formulation. The excipients in Brivaracetam Desitin 10 mg film-coated tablets include croscarmellose sodium, lactose monohydrate, microcrystalline cellulose (from the tablet core), as well as polyvinyl alcohol, macrogol, talc, titanium dioxide, and iron oxide yellow (from the film coating). Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine due to the presence of lactose.
If you have previously experienced an allergic reaction to any pyrrolidone-based medication, inform your prescribing physician before starting Brivaracetam Desitin. Signs of an allergic reaction may include skin rash, hives, itching, swelling of the face, lips, tongue, or throat, difficulty breathing, or anaphylaxis. While serious hypersensitivity reactions to brivaracetam are rare, they have been reported in post-marketing surveillance, including cases of bronchospasm and angioedema. If you experience any of these symptoms, stop taking the medication and seek immediate medical attention.
Warnings and Precautions
Antiepileptic drugs, including brivaracetam, have been associated with an increased risk of suicidal thoughts and behavior. A meta-analysis conducted by the FDA of 199 placebo-controlled clinical trials involving 11 different antiepileptic drugs found that patients receiving these medications had approximately twice the risk of suicidal ideation or behavior compared to those receiving placebo. Patients, caregivers, and family members should be alert to the emergence or worsening of depression, suicidal thoughts, unusual changes in mood or behavior, and should report any concerns to the treating physician immediately.
Before starting Brivaracetam Desitin, discuss the following important considerations with your healthcare provider:
- Psychiatric and behavioral effects: Brivaracetam may cause psychiatric symptoms including irritability, anxiety, aggression, depression, psychotic symptoms, and agitation. In clinical trials, psychiatric adverse events were reported in approximately 13% of brivaracetam-treated patients versus 8% of placebo patients. Patients with a history of psychiatric disorders may be at increased risk. While the incidence of behavioral side effects appears to be lower with brivaracetam than with levetiracetam, vigilance is still warranted. If you experience significant mood changes, contact your doctor.
- Dizziness and somnolence: Brivaracetam can cause dizziness and drowsiness, which may impair your ability to drive or operate machinery. These effects are most pronounced during the initial weeks of treatment or when the dose is increased. Avoid driving and hazardous activities until you know how this medication affects you. In clinical trials, dizziness was reported in approximately 11% and somnolence in approximately 15% of patients receiving brivaracetam.
- Abrupt withdrawal: Never stop taking Brivaracetam Desitin suddenly without medical supervision. Abrupt discontinuation of antiepileptic medications can trigger withdrawal seizures, including status epilepticus, which is a prolonged seizure that constitutes a medical emergency. If treatment needs to be discontinued, your doctor will gradually reduce the dose over at least one week.
- Hepatic impairment: Brivaracetam is extensively metabolized in the liver. Patients with hepatic impairment may have increased plasma concentrations of the drug. A lower starting dose and maximum dose are recommended for patients with chronic liver disease of any stage (Child-Pugh classes A, B, and C). If you have liver disease or a history of liver problems, inform your doctor before starting treatment.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking Brivaracetam Desitin. There is limited clinical data on the use of brivaracetam in pregnant women. Animal studies have shown reproductive toxicity at doses higher than those used clinically. Brivaracetam crosses the placenta in animals, and fetal exposure is expected in humans. All antiepileptic drugs carry potential risks during pregnancy, including an increased risk of congenital malformations. However, uncontrolled seizures during pregnancy also pose significant risks to both the mother and the developing baby, including physical injury, hypoxia, and in severe cases, death.
The decision to use Brivaracetam Desitin during pregnancy must be made carefully by you and your neurologist, weighing the benefits of continued seizure control against the potential risks to the fetus. Women of childbearing potential should use effective contraception during treatment and discuss pregnancy planning well in advance with their healthcare team. If you become pregnant while taking brivaracetam, do not stop the medication abruptly; contact your doctor immediately for guidance. Pregnancy registries exist to monitor outcomes in women exposed to antiepileptic drugs during pregnancy, and your doctor may recommend enrollment.
Brivaracetam is excreted in breast milk in animals. It is not known whether brivaracetam passes into human breast milk, but given its chemical properties (low protein binding, small molecular weight relative to antibodies, high oral bioavailability), it is likely that some amount would be present in breast milk. The decision to breastfeed while taking brivaracetam should be made in consultation with your doctor, considering the benefit of breastfeeding for the infant and the benefit of continued treatment for the mother.
Driving and Operating Machinery
Brivaracetam Desitin may have a moderate influence on the ability to drive and use machines. Due to possible differences in individual sensitivity, some patients might experience dizziness, somnolence, or other central nervous system symptoms, particularly at the beginning of treatment or after dose increases. Patients should be advised not to drive or operate complex machinery until they are familiar with the effects of brivaracetam on their ability to perform such activities. Additionally, epilepsy itself may affect the ability to drive; patients should follow local regulations regarding driving and seizure disorders.
How Does Brivaracetam Desitin Interact with Other Drugs?
Brivaracetam is primarily metabolized by hydrolysis of the acetamide moiety via amidase enzymes (which are not CYP-dependent) and, to a lesser extent, by hydroxylation mediated by the cytochrome P450 enzyme CYP2C19. At therapeutic concentrations, brivaracetam does not significantly induce or inhibit the major CYP enzymes (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4) or the drug transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). This gives brivaracetam a substantially better drug interaction profile compared to many older antiepileptic drugs such as carbamazepine, phenytoin, phenobarbital, and valproate, which are known to cause extensive enzyme induction or inhibition.
Despite this generally favorable profile, there are several clinically relevant interactions that should be taken into account:
Major Interactions
| Drug | Effect | Clinical Recommendation |
|---|---|---|
| Phenytoin | Brivaracetam increases phenytoin plasma levels by ~20–30% by inhibiting CYP2C19-mediated metabolism of phenytoin | Monitor phenytoin levels; dose adjustment of phenytoin may be required |
| Rifampicin | Rifampicin (a potent CYP enzyme inducer) decreases brivaracetam plasma levels by approximately 45% | Consider increasing brivaracetam dose when starting rifampicin; consider dose reduction when stopping |
| Carbamazepine | Carbamazepine (CYP3A4/CYP2C19 inducer) reduces brivaracetam levels by ~26%. Brivaracetam increases carbamazepine-epoxide (active metabolite) levels by ~37% | Monitor for carbamazepine-epoxide toxicity (dizziness, diplopia, nausea); brivaracetam dose adjustment may be needed |
| Phenobarbital / Primidone | These CYP enzyme inducers may decrease brivaracetam plasma levels | Monitor seizure control; brivaracetam dose increase may be necessary |
Minor Interactions and No Significant Interactions
Population pharmacokinetic analyses and dedicated interaction studies have shown that brivaracetam does not have clinically significant pharmacokinetic interactions with the following commonly used antiepileptic drugs: levetiracetam, valproate, lamotrigine, topiramate, oxcarbazepine (or its active metabolite monohydroxycarbamazepine), lacosamide, gabapentin, pregabalin, and zonisamide. No dose adjustments of these concomitant antiepileptic drugs are generally needed when starting or stopping brivaracetam.
| Drug / Category | Interaction Status |
|---|---|
| Oral contraceptives (ethinylestradiol/levonorgestrel) | No clinically significant interaction; contraceptive efficacy is not affected |
| Levetiracetam | No pharmacokinetic interaction, but clinical benefit of combination is reduced due to shared SV2A target |
| Valproate | No clinically significant interaction |
| Lamotrigine | No clinically significant interaction |
| Midazolam (CYP3A4 substrate) | No clinically significant interaction |
| Omeprazole (CYP2C19 substrate) | No clinically significant interaction at therapeutic brivaracetam doses |
| Alcohol (ethanol) | No pharmacokinetic interaction, but additive CNS depressant effects are possible; avoid or limit alcohol consumption |
While there is no pharmacokinetic interaction between brivaracetam and levetiracetam, the clinical benefit of combining these two drugs appears to be limited because they share the same molecular target (SV2A). In the pivotal clinical trials, the reduction in seizure frequency with brivaracetam was less pronounced in patients who were already taking levetiracetam. If your doctor is considering adding brivaracetam to your treatment, switching from levetiracetam to brivaracetam (rather than adding brivaracetam on top of levetiracetam) may be a more effective strategy.
Always inform your doctor, pharmacist, or nurse about all the medicines you are taking, have recently taken, or might take. This includes prescription drugs, over-the-counter medications, vitamins, minerals, and herbal or natural supplements. Some herbal products, such as St. John’s wort (Hypericum perforatum), are known to induce CYP enzymes and may decrease brivaracetam levels, although this specific interaction has not been formally studied.
What Is the Correct Dosage of Brivaracetam Desitin?
Brivaracetam Desitin should always be used exactly as your doctor has prescribed. The medication is taken orally, swallowed whole with a glass of water. The film-coated tablets should not be crushed, broken, or chewed, as this may affect the drug’s release characteristics and taste. Brivaracetam can be taken with or without food, as food does not significantly affect the extent of absorption (bioavailability remains approximately 100% regardless of food intake), although it may slightly delay the time to peak concentration.
Adults and Adolescents (16 Years and Older)
| Phase | Daily Dose | Administration | Notes |
|---|---|---|---|
| Starting dose | 50 mg/day (25 mg twice daily) | Twice daily, morning and evening | No titration needed; therapeutic dose from day 1 |
| Dose adjustment | 50–200 mg/day | Twice daily, morning and evening | Adjusted based on clinical response and tolerability |
| Maximum dose | 200 mg/day (100 mg twice daily) | Twice daily, morning and evening | Higher doses did not show additional benefit in clinical trials |
One of the notable practical advantages of brivaracetam is that it can be started at the full therapeutic dose of 50 mg/day without the need for a gradual titration period. This is in contrast to many other antiepileptic drugs (such as lamotrigine, topiramate, or perampanel) that require weeks of slow dose escalation. Depending on the patient’s response and tolerability, the physician may adjust the dose within the range of 50–200 mg/day. Any dose adjustments should ideally be made in weekly increments or decrements of 50 mg/day, to allow adequate time to assess the effects of each dose level. Clinical trial data suggests that the 100 mg/day and 200 mg/day doses may provide additional seizure reduction in some patients, but the side effect burden also increases with dose, so the lowest effective dose should be used.
Children (Under 16 Years)
The safety and efficacy of brivaracetam in children under 16 years of age have not been established for the 10 mg film-coated tablet formulation. For younger pediatric patients (aged 2 years and older, weighing 11 kg or more), brivaracetam may be available in other formulations (such as oral solution or other tablet strengths) with age- and weight-based dosing. Consult your healthcare provider or check the specific product information for pediatric dosing recommendations.
Elderly Patients
No dose adjustment is generally required for elderly patients based on age alone. Clinical trials included patients up to 80 years of age, and no significant differences in the safety or efficacy profile were observed compared to younger adults. However, elderly patients may be more susceptible to the central nervous system effects of brivaracetam (dizziness, somnolence) and may have age-related reductions in renal and hepatic function. Cautious dosing and careful clinical monitoring are recommended in this population.
Hepatic Impairment
Dose Adjustments for Liver Disease
Because brivaracetam is extensively metabolized in the liver, patients with hepatic impairment of any severity (Child-Pugh A, B, or C) have higher plasma drug levels. The following adjustments are recommended:
- Starting dose: 25 mg twice daily (50 mg/day)
- Maximum recommended dose: 75 mg twice daily (150 mg/day)
These dose adjustments apply to all stages of chronic liver disease. Close clinical monitoring is advised.
Renal Impairment
No dose adjustment is needed for patients with renal impairment, including those with severe kidney disease. Brivaracetam is primarily metabolized in the liver, and renal excretion of unchanged drug accounts for less than 1% of the administered dose. However, brivaracetam has not been specifically studied in patients undergoing hemodialysis. Due to its low molecular weight and low protein binding, brivaracetam is likely to be removed by dialysis. Supplemental dosing after dialysis sessions may be considered.
Missed Dose
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a forgotten dose, as this increases the risk of side effects. If you miss multiple doses, contact your doctor for advice. To minimize the chance of forgetting your medication, try to take it at the same times every day and consider using a pill organizer or setting reminders on your phone.
Overdose
If you suspect that you or someone else has taken too much Brivaracetam Desitin, contact a poison control center or go to the nearest emergency department immediately. There is limited clinical experience with brivaracetam overdose. In clinical development, doses up to 1,400 mg/day were administered to healthy volunteers without life-threatening adverse effects, but central nervous system symptoms including dizziness, nausea, somnolence, and balance disorders were prominent. There is no specific antidote for brivaracetam overdose. Treatment is supportive and symptomatic, including monitoring of vital signs. Hemodialysis may be considered as a method to remove the drug due to its low protein binding, although clinical experience is limited. Given the elimination half-life of approximately 9 hours, clinical monitoring should continue for at least 24–48 hours after suspected overdose.
What Are the Side Effects of Brivaracetam Desitin?
Like all medicines, Brivaracetam Desitin can cause side effects, although not everybody gets them. The side effects observed in clinical trials involving over 3,000 patients treated with brivaracetam have been characterized by their frequency as follows. Understanding these frequency categories helps put the risk of each side effect into context and enables informed discussions between patients and their healthcare providers.
In the controlled clinical trial program, the most frequently reported adverse reactions were dizziness (occurring in approximately 11% of patients on brivaracetam versus 7% on placebo), somnolence (approximately 15% versus 8%), and fatigue (approximately 9% versus 4%). These effects are related to brivaracetam’s mechanism of action in the central nervous system and are dose-dependent, meaning they are more likely to occur and more pronounced at higher doses. Most of these common side effects appeared during the first weeks of treatment and improved with continued use.
Very Common
May affect more than 1 in 10 people
- Somnolence (drowsiness, sleepiness) – reported in approximately 15% of patients in clinical trials
- Dizziness – reported in approximately 11% of patients, typically mild to moderate and more common at higher doses
Common
May affect up to 1 in 10 people
- Fatigue (tiredness, lack of energy)
- Nausea
- Depression
- Insomnia (difficulty sleeping)
- Irritability
- Anxiety
- Upper respiratory tract infections (common cold, flu-like symptoms)
- Decreased appetite
- Vertigo (sensation of spinning)
- Vomiting
- Constipation
Uncommon
May affect up to 1 in 100 people
- Suicidal ideation (thoughts of self-harm or suicide)
- Psychotic symptoms (hallucinations, paranoia)
- Aggression and agitation
- Abnormal behavior
- Neutropenia (low white blood cell count)
- Hypersensitivity reactions (allergic reactions)
Rare
May affect up to 1 in 1,000 people
- Suicidal attempt
- Angioedema (swelling of face, lips, tongue, or throat)
- Bronchospasm (difficulty breathing due to airway constriction)
The psychiatric and behavioral side effects of brivaracetam deserve particular attention. While all antiepileptic drugs carry some risk of psychiatric adverse effects, the SV2A-targeting class (brivaracetam and levetiracetam) has been particularly associated with behavioral changes. However, comparative data from both clinical trials and real-world observational studies suggest that brivaracetam may have a more favorable psychiatric side effect profile than levetiracetam. A systematic review and meta-analysis published in Epilepsia in 2021 found that non-psychotic behavioral adverse events were less frequent with brivaracetam than with levetiracetam. Several clinical studies have also reported improvements in behavioral symptoms when patients were switched from levetiracetam to brivaracetam, supporting the clinical perception of a better behavioral tolerability profile.
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to your national adverse drug reaction reporting system. By reporting side effects, you can help provide more information on the safety of this medicine.
Contact your doctor or go to the emergency department immediately if you experience: suicidal thoughts or thoughts of self-harm; severe allergic reaction (swelling of face, lips, tongue, or throat; difficulty breathing; widespread skin rash); sudden worsening of seizures; or significant mood or behavioral changes including severe aggression, psychosis, or confusion.
How Should You Store Brivaracetam Desitin?
Proper storage of Brivaracetam Desitin is important to maintain the quality, safety, and efficacy of the medication throughout its shelf life. The film-coated tablets should be stored at room temperature, not exceeding 25°C (77°F). Store the tablets in their original blister packaging to protect them from moisture and light, as exposure to humidity and ultraviolet radiation can degrade the active ingredient over time. Do not transfer the tablets to another container unless it provides equivalent protection.
Keep this medicine out of the sight and reach of children. Children are at particular risk from accidental ingestion of antiepileptic medications, which can cause serious adverse effects including excessive drowsiness, respiratory depression, and, in severe cases, coma. Store the medication in a secure location that is not easily accessible to young children.
Do not use Brivaracetam Desitin after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month. If you notice any visible signs of deterioration, such as discoloration of the tablets, crumbling, or an unusual odor, do not use the medication and consult your pharmacist for advice. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use, as proper disposal helps to protect the environment and prevents accidental exposure.
What Does Brivaracetam Desitin Contain?
Understanding what a medication contains is important for several reasons: it allows patients and healthcare providers to identify potential allergens, it helps distinguish between different products that contain the same active ingredient, and it provides information about the tablet’s physical characteristics for identification purposes.
Active Ingredient
Each film-coated tablet contains 10 mg of brivaracetam. Brivaracetam (chemical name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) is a white to off-white crystalline powder with a molecular weight of 212.29 g/mol. It is freely soluble in water and in most organic solvents, which contributes to its rapid and nearly complete oral absorption.
Inactive Ingredients (Excipients)
Tablet core: Croscarmellose sodium (a disintegrant that helps the tablet break apart in the gastrointestinal tract), lactose monohydrate (a filler), and microcrystalline cellulose (a binder and filler that provides structural integrity to the tablet).
Film coating: Polyvinyl alcohol (a film-forming polymer), macrogol (polyethylene glycol, a plasticizer), talc (a glidant and anti-adherent), titanium dioxide (E171, a white opacifier), and iron oxide yellow (E172, a colorant that gives the tablet its characteristic appearance).
Appearance
Brivaracetam Desitin 10 mg film-coated tablets are small, round or oval, yellowish film-coated tablets. They may bear an imprint or score line for identification purposes. The exact appearance may vary between batches and manufacturers; always verify the appearance against the description in the patient information leaflet supplied with your medication.
Brivaracetam Desitin 10 mg tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. The amount of lactose per tablet is small (typically less than 100 mg), but patients with severe lactose intolerance should discuss this with their doctor or pharmacist.
Frequently Asked Questions About Brivaracetam Desitin
Brivaracetam Desitin is a prescription antiepileptic medication used as adjunctive therapy (add-on treatment) for partial-onset seizures (also called focal seizures) with or without secondary generalization in adults and adolescents from 16 years of age. It works by binding to synaptic vesicle protein 2A (SV2A) in the brain, reducing abnormal electrical activity that causes seizures. It is not intended for use as a sole treatment (monotherapy) for epilepsy.
Both brivaracetam and levetiracetam target the same molecular protein, SV2A, but brivaracetam was specifically designed to bind with 15–30 times greater affinity and selectivity. This higher binding affinity allows for therapeutic efficacy at lower doses and without the need for slow titration. Clinical evidence also suggests that brivaracetam may have a more favorable behavioral and psychiatric side effect profile than levetiracetam, with fewer reports of irritability and aggression. However, they should generally not be used together, as the clinical benefit of the combination is limited due to their shared mechanism of action.
While there is no direct pharmacokinetic interaction between brivaracetam and alcohol (they do not affect each other’s blood levels), combining them can have additive central nervous system depressant effects. This means that drinking alcohol while taking brivaracetam may increase drowsiness, dizziness, and impair coordination and judgment more than either substance alone. Additionally, excessive alcohol consumption can lower the seizure threshold, potentially worsening seizure control. It is generally recommended to avoid or significantly limit alcohol intake while taking antiepileptic medications. Discuss your alcohol use with your doctor.
If you forget to take a dose of Brivaracetam Desitin, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Never take a double dose to compensate for a forgotten one. Missing a single dose is unlikely to cause a seizure in most patients, but regularly missing doses can reduce the effectiveness of your treatment and increase the risk of breakthrough seizures. Consider using pill organizers, alarm reminders, or smartphone apps to help maintain a consistent dosing routine.
The film-coated tablets should ideally be swallowed whole with water. Crushing, breaking, or chewing the tablets is generally not recommended, as the film coating is designed to mask the bitter taste of brivaracetam and to protect the tablet from moisture. If you have difficulty swallowing tablets, speak with your doctor or pharmacist about alternative formulations, such as an oral solution, which may be available and can be easier to administer. Do not change the way you take your medication without first consulting your healthcare provider.
Brivaracetam has a rapid onset of action compared to many other antiepileptic drugs. After oral administration, it is absorbed rapidly and almost completely, reaching peak blood levels within approximately 1 hour. Clinical effects, in terms of seizure reduction, can be observed within the first few days of treatment. Unlike many other antiepileptic drugs, brivaracetam can be initiated at a therapeutic dose without requiring a slow titration period, which means patients can benefit from seizure reduction from the very beginning of treatment. The full therapeutic effect may continue to develop over the first few weeks as steady-state plasma concentrations are achieved (typically within 2 days with twice-daily dosing).
References
- European Medicines Agency (EMA). Briviact (brivaracetam) Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Briviact (brivaracetam) Prescribing Information. Revised 2024. Available at: www.accessdata.fda.gov
- Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890-1898. doi:10.1111/epi.13212
- Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47-56. doi:10.1111/epi.12432
- Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57-66. doi:10.1111/epi.12433
- Toledo M, Whitesides J, Engel J Jr, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016;57(7):1139-1151. doi:10.1111/epi.13416
- International League Against Epilepsy (ILAE). Treatment Guidelines: Evidence-Based Analysis of Antiseizure Medication Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. 2022.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. Updated 2024. Available at: www.nice.org.uk
- Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016;86(14):1344-1352. doi:10.1212/WNL.0000000000002545
- Yates SL, Fakhoury T, Liang W, Knoll K, Lee DA. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy & Behavior. 2015;52(Pt A):165-168. doi:10.1016/j.yebeh.2015.09.005
Medical Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – Specialists in Neurology and Clinical Pharmacology
Medical Review
Reviewed by iMedic Medical Review Board according to international guidelines (ILAE, EMA, FDA, NICE)
Evidence Standard
GRADE Evidence Framework – Level 1A: Systematic reviews and meta-analyses of randomized controlled trials
Editorial Independence
No pharmaceutical company funding or sponsorship. All content is independently researched and reviewed.
This article was last medically reviewed on . For questions or feedback, please contact us.